On August 20, 2026 IntraGel Therapeutics, developer of next generation long-acting injectables, reported an equity investment agreement and a strategic Option and Research License Agreement (the Option Agreement) with UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In a related equity investment agreement, UroGen will invest up to $7 million in the equity securities of IntraGel, which will support the Phase 2 clinical development of TumoCure, IntraGel’s investigational therapy for advanced head and neck cancer. Under the related Option Agreement, UroGen receives an exclusive option to obtain an exclusive, worldwide license to develop and commercialize TumoCure following IntraGel’s completion of a Phase 2 clinical study. In addition, UroGen gains access to IntraGel’s proprietary SRGel platform, a biodegradable sustained-release formulation technology designed for localized drug delivery, through a research license and options to obtain an exclusive, worldwide license to develop and commercialize up to three additional oncology products combining the SRGel platform with compounds to be designated by UroGen.

"UroGen’s leadership in localized oncology therapies and commercial-stage experience make them an ideal collaborator to help advance the SRGel platform and accelerate the development of TumoCure," said Peter Siman, Ph.D., Chief Executive Officer and Co-Founder, IntraGel Therapeutics. "We see this collaboration as an important validation of our SRGel platform and the clinical potential of our lead investigational product, TumoCure, while creating a strong pathway to accelerate development across multiple oncology indications."

"This agreement represent an important step in expanding UroGen’s oncology pipeline and our technological capabilities," said Liz Barrett, President and Chief Executive Officer of UroGen Pharma. "IntraGel’s biodegradable, sustained-release technology complements our expertise in local drug delivery while creating significant optionality for future innovation. Beyond the opportunity to advance TumoCure, we believe the SRGel platform could potentially enable multiple therapeutic approaches across a range of solid tumors and provide a foundation for new product opportunities over time."

Dr. Siman added, "In parallel, we are continuing to advance additional therapeutic candidates in our pipeline based on the broadly applicable SRGel platform including our internally developed IG-003 with GLP-1 analogues for weight management, and monoclonal antibody and peptide programs developed through ongoing collaborations."

SRGel is a biodegradable depot technology designed to enable sustained release of therapeutic agents over extended periods. The platform’s flexibility supports multiple therapeutic modalities and indications. In oncology, SRGel has potential applicability across a broad range of solid tumor settings, including bladder, skin, brain, gastrointestinal and testicular cancers, creating opportunities for future localized oncology treatments beyond the initial collaboration programs.

TumoCure is an investigational cisplatin product formulated with IntraGel’s proprietary SRGel platform, designed to enable prolonged localized drug exposure while limiting systemic exposure. Presented at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, Phase 1b clinical data demonstrated that TumoCure was generally safe and well tolerated, showed low systemic cisplatin exposure, and provided early indications of anti-tumor activity in a heavily pretreated patient population, including patients with cisplatin treatment-resistant disease1. Investigators also reported improvements in tumor-related symptoms in certain patients. These findings support continued clinical development of TumoCure and further expansion of the SRGel platform as a potential approach for sustained local therapy across additional solid tumors while minimizing systemic exposure.

About SRGel

SRGel is IntraGel’s proprietary injectable hydrophobic gel-like drug delivery platform designed to enable sustained, tailored drug release. Built on a proprietary water-free and solvent-free fatty-acids based polymer matrix, SRGel is engineered to provide controlled, and prolonged release of therapeutics agents following a single administration, with applicability for both localized delivery at the target site and sustained systemic exposure. The technology is designed, when injected intratumorally, to maintain high local drug concentrations while minimizing systemic exposure and associated toxicities. SRGel is compatible with a broad range of therapeutic modalities, including small molecules, peptides and biologics, and may be applicable across therapeutic areas and indications, including weight loss management and inflammatory diseases.

About TumoCure

TumoCure is IntraGel’s lead product candidate and the first clinical application of the SRGel platform. TumoCure consists of cisplatin incorporated into the SRGel biodegradable matrix and is administered as a single intratumoral injection. The investigational therapy is designed to provide sustained delivery of cisplatin directly within tumor tissue over several months while limiting systemic exposure. TumoCure is Phase 2-ready and is being developed for patients with locally advanced, inoperable head and neck cancers, who are ineligible for systemic cisplatin-based chemoradiation. IntraGel is pursuing development through the U.S. Federal Drug Administration (FDA)’s 505(b)(2) regulatory pathway and believes the technology may have future applicability across additional solid tumor indications, including lung, brain, gastrointestinal, ovarian and testicular cancers.

(Press release, IntraGel Therapeutics, AUG 20, 2026, View Source [SID1234670258])

On August 20, 2026 Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for safusidenib, the company’s investigational, oral, brain-penetrant selective inhibitor of mutant IDH1.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"People with IDH1-mutant glioma urgently need additional treatment options. We were eager to pursue Fast Track Designation for safusidenib to hopefully reach these patients on an expedited timeline," said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. "We look forward to working with the FDA as we advance our mission to provide an effective therapy to nearly every patient whose life is impacted by this disease."

FDA Fast Track Designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and address unmet medical need. The designation provides for more frequent interactions with the FDA throughout a drug’s development. If relevant criteria are met, the designation may allow for rolling review of a marketing application, permitting completed sections to be submitted for FDA review as they become available, rather than waiting for the entire application to be complete. These benefits have the potential to shorten the time it takes to bring safusidenib to patients.

The designation was granted based on favorable data from the safusidenib clinical program to date. Most recently, Nuvation Bio announced updated data from the Phase 2 J201 study demonstrating durable responses and a favorable risk-benefit profile over long-term follow-up. Specifically, at a median follow-up of 38.8 months in the J201 study, treatment with safusidenib showed a confirmed objective response rate (cORR) of 51.9%, with median progression-free survival (PFS) not yet reached and a 36-month PFS rate of 79.1%, and only one patient who had previously responded experienced subsequent disease progression. No new safety signals have been identified with longer-term follow-up. These results build upon findings previously published in Neuro-Oncology.

About IDH1-mutant Glioma
Gliomas are the most common type of brain cancer in adults worldwide. In the U.S., nearly 2,500 people are diagnosed with IDH-mutant gliomas each year, of which more than 95% harbor a mutation in the IDH1 gene. Most patients are diagnosed in their 30s and 40s. While patients with IDH1 mutations generally have longer survival times than those with wild-type IDH1, gliomas are not currently curable and prognosis worsens for those with high-risk features, including high grade tumors.

About Safusidenib
Safusidenib is an investigational, oral, brain-penetrant, selective inhibitor of mutant IDH1. It is being studied in patient populations with significant unmet medical need, including settings where there are limited or no approved targeted treatment options. In Phase 1 and Phase 2 clinical studies, safusidenib demonstrated encouraging clinical activity, including delayed disease progression and durable responses across a range of tumor grades and risk groups, with a favorable risk-benefit profile. These early findings support further investigation of safusidenib in the currently enrolling Phase 3 SIGMA study, as well as in the Phase 3 G307 study outside the U.S. where vorasidenib is not yet approved or accessible and the Phase 2 G209 study in a post-vorasidenib setting.

In August 2026, the FDA granted Fast Track Designation to safusidenib in IDH1-mutant glioma.

About the SIGMA (G203) Study
SIGMA is a pivotal Phase 3 study that will evaluate safusidenib compared to placebo as a maintenance therapy after standard-of-care in IDH1-mutant astrocytoma with high-risk features. The pivotal portion of the study will enroll approximately 300 patients.

A separate, exploratory, non-pivotal cohort will evaluate safusidenib in participants with grade 3 IDH1-mutant oligodendroglioma who have not yet received chemotherapy or radiotherapy. The primary endpoint is objective response rate. This cohort is expected to enroll approximately 40 patients.

(Press release, Nuvation Bio, AUG 20, 2026, View Source [SID1234670257])

On August 20, 2026 Keymed Biosciences (HKEX: 02162) reported its interim results for the six months ended June 30, 2026. Guided by a clear dual-engine driven strategy, the company demonstrated outstanding execution capabilities: In the domestic market, following the successful commercialization and implementation of medical insurance coverage for the core product Kangyueda, the company’s highly qualified in-house marketing team rapidly stepped up its efforts, driving a robust breakthrough in domestic commercialization revenue from "1 to N", and providing the Company with a robust cash flow and a solid performance foundation. In the overseas market, the research and development capabilities of Keymed continued to be recognized by multinational pharmaceutical companies. Overseas out-licensing collaborations in respect of its key pipelines and their steady clinical advancement not only validated the Company’s innovative capabilities, but also generated substantial upfront payments and milestone revenue. The steady increase in domestic sales and the continued advancement of overseas (BD) activities complemented each other, establishing a dual-engine driven growth model with exceptional resilience and explosive growth potential.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Rapid Growth in Sales Revenue, and Cash Flows Contribution from Business Development

In the first half of 2026, the company achieved total revenue of RMB617 million, mainly boosted by the strong performance of our commercialization product, Kangyueda’s revenue increased by 132% to RMB393 million. Collaboration revenue amounted to RMB224 million for the six months ended June 30, 2026, primarily attributable to the milestone payment received under the exclusive license agreement with AstraZeneca AB, attesting to the robust potential of our pipeline. Profit for the period reached RMB1,220 million. The swing from loss to profit was primarily driven by the successful merger and acquisition of our NewCo by MNC and rapid revenue growth, alongside enhancement in operational efficiency. The Company’s cash reserves (including cash and cash equivalents, time deposits, and financial assets at FVTPL) amounted to approximately RMB3.24 billion, providing a solid financial foundation for its sustainable growth and global innovation.

Dual-wheel Drive Fully Launched, Pipeline Portfolio Gaining Momentum

In 2026, Kangyueda entered the first year of full-scale volume growth under medical insurance coverage. As of June 30, 2026, the Company’s commercialisation team comprised nearly 500 personnel, covering more than 1,600 hospitals and over 260 cities, with market access initiatives progressing rapidly. Kangyueda generated sales revenue of RMB393 million, representing a year-on-year increase of 132%. In July 2026, Kangyueda was officially included in the National Essential Medicines List (2026 Edition), which took effect on September 1, 2026. Pursuant to the relevant administrative requirements for essential medicines, public medical institutions at all levels nationwide are required to procure and give priority to the use of medicines included in the list. Such inclusion is conducive to enabling Kangyueda to overcome its previous limitations in Grade III Class A hospitals, accelerating its penetration into county-level and primary healthcare markets, broadening terminal prescription settings and further enhancing the accessibility of the medicine.

In January and March 2026, the marketing applications for Stapokibart for the treatment of moderate-to-severe AD in adolescents and prurigo nodularis (PN) were accepted by the NMPA. Concurrently, we are advancing a randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of Stapokibart in pediatric subjects with moderate-to-severe AD. As of the date of this announcement, patient enrollment is ongoing. In July 2026, we initiated a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of Stapokibart injection with background therapy for the treatment of adolescent patients with SAR.

BD Milestone Realization Drives Further Acceleration of Global R&D

CM336 (BCMA x CD3 bispecific antibody): On June 5, 2026, the Group’s NewCo partner, Ouro Medicines, was successfully acquired by Gilead and Lakefront (Euronext & Nasdaq: LKFT, formerly known as Galapagos), and the transaction has been officially completed. The Group has received an upfront payment of US$257 million, and is entitled to receive milestone payments of up to approximately US$70 million. In addition, the exclusive license agreement entered into between the Group and Ouro Medicines in November 2024 remains in effect. The milestone payments of up to US$610 million will be fulfilled by Gilead and Lakefront, and the tiered royalties on net sales ranging from high single digits to mid-double digits will be fulfilled by Gilead. Through this transaction, Lakefront acquired substantially all of the team and operating assets of Ouro Medicines, and will collaborate with Gilead on the subsequent development of CM336/OM336. Lakefront will be responsible for the ongoing and future Phase I/II clinical studies of CM336/OM336, while Gilead will lead the pivotal registrational and late-stage studies. The exclusive global commercialisation rights (excluding the Greater China region) are solely owned by Gilead.
CMG901/AZD0901 (Claudin 18.2 ADC): The CLDN18.2 ADC, in collaboration with AstraZeneca, is leading the global clinical development timeline among the first tier. CMG901/AZD0901 has obtained Fast Track Designation and Orphan Drug Designation from the FDA for second-line or later gastric cancer as well as Breakthrough Therapy Designation from the CDE, with OS demonstrating a statistically significant and highly clinically meaningful benefit (CLDN18.2 expression rate ≥25% for enrolled subjects). The global multi-center Phase III clinical trial for first-line gastric cancer completed its first patient enrollment in early 2026, and the perioperative gastric cancer study is in the Phase II clinical stage. The development is further differentiated by expanding into additional tumor types, including biliary tract cancer and pancreatic cancer.
CM355/PRO-203 (CD20 x CD3 bispecific antibody): Prolium continues to advance an international multi-center Phase I/II clinical study of CM355/PRO-203 for SSc, and completed the dosing of the first patient with systemic sclerosis in June 2026, and will also initiate therapeutic studies for other B-cell-driven severe autoimmune diseases within 2026.
Intensive Pipeline Breakthroughs, Next-generation blockbuster lead a new iteration

CM512 (a TSLP/IL-13 bispecific antibody): Next-generation blockbuster CM512 is poised to succeed Kangyueda and lead a new iteration of autoimmune disease treatment. As the world’s first IgG-like long-acting dual TSLP/IL-13 inhibitor, CM512 has a half-life of up to 70 days, has met all clinical endpoints in the Phase II clinical trial for CRSwNP. CM512 demonstrates a rapid onset of action, capable of rapidly shrinking nasal polyps at week 4 post-dosing while significantly improving nasal congestion and promoting the recovery of olfactory function. The efficacy of a single injection can be maintained for six months. At week 24, its change from baseline in the Nasal Polyp Score (NPS) was significantly superior to that of the control group, while overall inflammation of the sinus cavity was significantly reduced, and its Phase III clinical trial has been rapidly initiated. The Company has also established a presence in indications including moderate-to-severe asthma, moderate-to-severe COPD, moderate-to-severe AD in adults, perennial allergic rhinitis, and chronic spontaneous urticaria.
CM336 (BCMA x CD3 bispecific antibody): In the field of autoimmune diseases, we continued to advance an open-label, multi-center Phase II clinical study to evaluate the efficacy and safety of CM336 injection for the treatment of relapsed or refractory primary light-chain amyloidosis in the first half of 2026, and this study is currently in the patient enrollment phase. In May 2026, CM336, intended for the treatment of relapsed or refractory light-chain amyloidosis in patients previously treated with bortezomib and CD38 monoclonal antibody (mAb), was included in the Breakthrough Therapy Designation list.
In the first half of 2026, we continued to advance a Phase I/II clinical study to evaluate the safety and efficacy of CM336 injection for the treatment of subjects with relapsed or refractory autoimmune cytopenias. As of the date of this announcement, patient enrollment for Phase I of the clinical study has been completed. In July 2026, an open-label Phase Ib study was initiated to evaluate CM336 injection in patients with active Sjögren’s syndrome.

In the field of oncology, the IND application for the Phase III clinical trial of CM336 in combination with CM313 (a CD38 mAb) for second-line or later-line RRMM was accepted by the National Medical Products Administration (the "NMPA") on July 3, 2026. The study is divided into two parts: Part 1 is a non-randomized safety run-in phase, and Part 2 is a randomized controlled registration cohort, which will evaluate multiple dosing regimens compared to SOC. The trial will be initiated upon receipt of the clinical trial approval.

Other Pipeline Programs Progressing Steadily:
CM313: Continued to advance a randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the safety and efficacy of CM313 (SC) injection in subjects with IgA nephropathy. As of the date of this announcement, this study is in the patient enrollment phase.

CM518D1: Continued to advance a multi-center, open-label Phase I/II clinical trial.

To date, the Company has submitted Investigational New Drug (IND) applications for multiple pipeline candidates, including CM529D1 (a DLL3/SEZ6 bispecific ADC) for small cell lung cancer, CM583 (a long-acting CGRP/PACAP bispecific antibody) for migraine, and CM551 (a long-acting TL1A/IL-23 p19 bispecific antibody) for inflammatory bowel disease.

We expect that multiple First-in-Class pipeline candidates will enter the IND and clinical stages, including long-acting bispecific antibodies, bispecific ADCs, siRNA and Protac, to address global unmet medical needs in chronic diseases and oncology.

Sustained Momentum in R&D, Production, and Talent Solidifies the Foundation

We have built 6 fully-integrated platforms to enable our in-depth R&D in the areas of immunology and oncology including: Antibody Discovery Platform, KeyMedSTAR ADC Platform, TCE Bispecific Antibody Platform, VESIR Oligonucleotide Platform, Small Molecule Platform and KeyCND Blood-Brain Barrier-Penetrating Antibody Delivery Platform. Our platforms are integrated seamlessly to support key drug development functionalities, including antibody screening, small molecule lead compound discovery, antibody conjugation, functional evaluation, in vivo preclinical studies and biomarker identification. We have the expertise and capability to independently complete the entire drug development process from drug discovery to preclinical research to clinical development and to NDA/BLA application.

To ensure production and supply of high-quality and affordable antibody drugs, we have always been committed to enhancing our in-house manufacturing capabilities. We have internally developed high-expressing cell lines to ensure high yield and low costs for our antibody drugs manufacturing. As of the date of this announcement, the production base in Chengdu has 3 pilot production lines and 3 commercial production lines, with a total production capacity of 21,800 litres. The stainless steel production lines with an additional production capacity of 24,000 litres have completed installation and commissioning and will soon be put into use. All such designs comply with the cGMP requirements of the NMPA and the FDA.

As of June 30, 2026, we had 1,768 full-time employees in total, including nearly 500 employees engaging in commercialization and nearly 420 employees engaged in drug discovery and clinical operations. We will continue to recruit talent to meet the growing needs of commercial sales of products, research and development, clinical, production and the Company’s operations.

Standing at the brand-new starting point of its tenth anniversary, Keymed will continue to uphold its "patient-centric" original aspiration. Leveraging the robust momentum of its dual-drive strategy, the Company will accelerate the research and development and commercialisation process of its global pipeline, committing to providing more high-quality and accessible innovative therapies for patients worldwide, and creating long-term, sustainable, and exceptional value for Shareholders.

(Press release, Keymed Biosciences, AUG 20, 2026, View Source [SID1234670256])

On August 20, 2026 UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, reported a strategic Option and Research License Agreement (the Option Agreement) and a related equity investment agreement (the Investment Agreement) with IntraGel Therapeutics, Ltd. (IntraGel).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Option Agreement includes two strategic components. First, UroGen gains access to IntraGel’s proprietary SRGel platform, a biodegradable, sustained-release formulation technology designed for localized drug delivery, through a research license and options to obtain an exclusive, worldwide license to develop and commercialize up to three additional oncology products combining the SRGel platform with compounds to be designated by UroGen. Second, UroGen receives an exclusive option to obtain an exclusive, worldwide license to develop and commercialize TumoCure, IntraGel’s investigational therapy for advanced head and neck cancer, following IntraGel’s completion of a Phase 2 clinical study.

"This Option Agreement represents an important step in expanding UroGen’s oncology pipeline and technological capabilities," said Liz Barrett, President and Chief Executive Officer of UroGen. "IntraGel’s biodegradable, sustained-release technology complements our expertise in local drug delivery while creating significant optionality for future innovation. Beyond the opportunity to advance TumoCure following a Phase 2 clinical study, we believe the SRGel technology could potentially enable multiple therapeutic approaches across a range of solid tumors and provide a foundation for new product opportunities over time."

In connection with the Option Agreement, UroGen has also entered into an Investment Agreement with IntraGel, pursuant to which UroGen will invest up to $7 million in the equity securities of IntraGel.

SRGel is a biodegradable depot technology designed to enable sustained local release of therapeutic agents over extended periods. The platform’s flexibility supports multiple therapeutic modalities and has potential applicability across a broad range of solid tumor settings.

"UroGen’s leadership in localized oncology therapies and commercial-stage experience make them an ideal partner to help advance the SRGel platform and accelerate the development of TumoCure," said Peter Siman, Ph.D., Chief Executive Officer and Co-Founder of IntraGel. "We see in this collaboration an important validation of the SRGel platform and the clinical potential of our lead product candidate, TumoCure, while creating a strong pathway to accelerate development across multiple oncology indications."

TumoCure is an investigational cisplatin treatment formulated with IntraGel’s proprietary SRGel platform, designed to enable prolonged localized drug exposure while limiting systemic exposure.

Presented at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, early clinical data (N=8) showed that TumoCure was generally well tolerated in Phase 1b patients, showed low systemic cisplatin exposure, and provided early indications of anti-tumor activity in a heavily pretreated patient population, including patients with cisplatin treatment-resistant disease. Investigators also reported improvements in tumor-related symptoms in certain patients. These findings support continued clinical development of TumoCure and further expansion of the SRGel platform as a potential approach for sustained local therapy across additional solid tumors with the goal of minimizing systemic exposure.

About SRGel

SRGel is IntraGel’s proprietary injectable hydrophobic gel-like drug delivery platform designed to enable sustained drug release directly within solid tumors. Built on a proprietary water-free and solvent-free fatty-acids based polymer matrix, SRGel is engineered to provide controlled, and prolonged release of therapeutic agents following a single administration, with applicability for both localized delivery at the target site and sustained local exposure.

The technology is designed, when injected intratumorally, to maintain high local drug concentrations while minimizing systemic exposure and associated toxicities. SRGel has shown early indications of compatibility with a broad range of therapeutic modalities, including small molecules, peptides and biologics, and may be applicable across various therapeutic areas and indications, including weight loss management and inflammatory diseases.

About TumoCure

TumoCure is IntraGel’s lead product candidate and the first clinical application of the SRGel platform. TumoCure consists of cisplatin incorporated into the SRGel biodegradable matrix and is administered as a single intratumoral injection. The investigational therapy is designed to provide sustained delivery of cisplatin directly within tumor tissue over several months while limiting systemic exposure.

TumoCure is Phase 2-ready and is currently being developed for patients with locally advanced, inoperable head and neck cancers, who are ineligible for systemic cisplatin-based chemoradiation. IntraGel is pursuing development through the U.S. Federal Drug Administration (FDA)’s 505(b)(2) regulatory pathway and believes the technology may have future applicability across additional solid tumor indications, including lung, brain, gastrointestinal, ovarian and testicular cancers.

(Press release, UroGen Pharma, AUG 20, 2026, View Source [SID1234670255])

On August 20, 2026 Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company") reported data from two scientific posters presented at the 2026 Society for Neuro-Oncology/American Society of Clinical Oncology (SNO/ASCO) CNS Metastases Conference, held August 13–15 in Boston. One presentation featured updated pharmacokinetic (PK), pharmacodynamic (PD), dosimetry, safety and activity data for REYOBIQ (rhenium-186 obisbemeda) in patients with leptomeningeal metastases (LM), including emerging safety data from the ongoing repeated-dosing program. The second was an update of a previously reported health economics analysis evaluating the impact of CNSide-enabled earlier LM detection and therapeutic management.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The data presented at SNO/ASCO underscore the rationale behind Cerenome’s integrated approach to leptomeningeal metastases – from earlier and more definitive detection and quantitative disease monitoring with CNSide, to targeted local therapy with REYOBIQ," said Marc H. Hedrick, M.D., Cerenome President and Chief Executive Officer. "The REYOBIQ findings provide additional support for broad CSF distribution, limited systemic exposure in most patients, and the continued evaluation of repeat dosing. The CNSide analysis reinforces the potential economic value of earlier, information-rich disease management. Together, these data demonstrate the potential of connecting diagnostics, therapeutics and longitudinal data to improve the management of CNS cancers."

As previously announced, both posters will be available on the Publications page of Cerenome’s website following the conclusion of the conference.

REYOBIQ ReSPECT-LM and ReSPECT-LMM Data

A poster titled, "ReSPECT-LM: Pharmacokinetic and Pharmacodynamic Assessment of Rhenium Obisbemeda in Leptomeningeal Metastases with Emerging Data from Repeated Dosing (ReSPECT-LMM)" was presented by Andrew Brenner, M.D., Ph.D., of The University of Texas Health Science Center at San Antonio. The analysis included updated safety, activity, PK and dosimetry findings from the single-administration study, along with emerging data from the ongoing repeated-dosing program.

Key findings included:

In the ongoing repeated-dosing ReSPECT-LMM study, Cohort 1a cleared with no dose-limiting toxicities, with enrollment ongoing in additional cohorts.
PK showed rapid ( ̴24 hours) redistribution of drug within the CSF with clearance of the REYOBIQ from the lateral ventricle at a half-life of 1.7 hours. By clearing the ventricles quickly, drug remains available at high doses in the cerebral spinal fluid.
Bulk RNA-Seq demonstrated rapid ( ̴5 hours) induction of cell-death (apoptosis) genes, with peak activity occurring at 24 hours. Data promoting cell-death supports REYOBIQ’s established radiopharmaceutical mechanism of action and highlights its rapid onset target activity.
CNSide Cost-of-Care Analysis

The second poster, titled, "Economic Impact of Earlier Detection and Therapeutic Management of Leptomeningeal Metastases Using CNSide: A Cost-of-Care Analysis," was presented by Kelly Kreitzburg Ondrasek, Ph.D., Medical Science Liaison at CNSide Diagnostics. The analysis evaluated the potential economic and clinical impact of a CNSide-enabled care pathway incorporating earlier definitive LM diagnosis, targeted treatment, and quantitative disease monitoring.

The model estimated average LM-related treatment costs of approximately $119,550 per month, or approximately $717,300 over six months. Under modeled scenarios incorporating earlier LM confirmation and optimized management, a CNSide-enabled pathway was estimated to reduce monthly LM-related costs by approximately 33-47%.

(Press release, Cerenome, AUG 20, 2026, View Source [SID1234670254])